Expert view: Opportunities in flow cytometry
New therapies that direct the immune system to identify and destroy cancer cells, such as CAR-T and immune checkpoint inhibitors, have revolutionised cancer treatment.
To improve the efficacy of these breakthrough medicines and discover new therapies, there is a need for more physiologically cell-based disease models. Multiplex analysis that combines immuno-phenotyping and functional assessment of cell health, activation, killing potential and cytokine profiling is required to identify and validate new cancer targets and approaches. Severe constraints on both primary cell availability and long-term viability are driving the desire to miniaturise assays and compress analysis workflows. One solution for improving the scale and throughput of novel immunebased therapies is to use improved/advanced bioanalytical instruments in targeted clinical applications.